Key facts
- Merck KGaA has agreed to acquire Bio-Techne Corp. for $73 per share.
- The total enterprise value of the acquisition is approximately $11.3 billion.
- The offer price represents a 36% premium over Bio-Techne's one-month volume-weighted average share price.
German science and healthcare company Merck KGaA has entered into an agreement to acquire the biotech firm Bio-Techne Corp. for $73 per share in an all-cash transaction. The deal values Bio-Techne at approximately $11.3 billion on an enterprise value basis. According to Merck KGaA, the offer price reflects a 36% premium over Bio-Techne's one-month volume-weighted average share price.